You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SBIR Phase II: Building Mathematical Thinking and Problem-solving Skills Together Through Play

    SBC: MATHBRIX LLC            Topic: LC

    This SBIR Phase I project will develop a machine learning-assisted family math preparation program that will help and encourage parents to provide early math instruction to young children, ages 4-8. Along with reading, developing mathematical proficiency is arguably one of the most important skills for young children to acquire, particularly with the growing importance of STEM (science, technology ...

    SBIR Phase II 2023 National Science Foundation
  2. Developing a clinical diagnostic tool for age-related cochlear synaptopathy.

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIA

    Age-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma

    SBC: Sarya, LLC            Topic: 102

    PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Low-Dose Magneto-Thrombolysis to Expand Stroke Care

    SBC: UNANDUP, LLC            Topic: 106

    Acute ischemic stroke (AIS) results from a blood clot in the neurovasculature and is a leading cause of death and neurological disability in the United States (US). AIS impacts more than 700,000 Americans annually, with a 65% chance of death or severe disability. By 2030, it is expected that the AIS economic burden will exceed $180B in the US alone.Standard AIS therapies include FDA-approved throm ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Framewise Integrated Real-Time MRI Monitoring (FIRMM) software commercialization readiness for clinical care

    SBC: TURING MEDICAL TECHNOLOGIES INC            Topic: 102

    Project Abstract/SummaryMotion related artifacts are a significant source of cost to the healthcare system. With over 12,000 MRI scanners in the U.S. and estimates that $434,000 are lost per scanner each year, motion in MRIs is costing our health care system approximately $4B yearly. Our FDA-cleared software solution Framewise Integrated Real- Time MRI Monitoring (FIRMM) mitigates data lost due to ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Group B Streptococcus bioconjugate vaccine

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Streptococcus agalactiae, commonly referred to as Group B Streptococcus (GBS), is a leading cause of neonatal meningitis and sepsis worldwide. GBS neonatal disease manifests as early onset invasive disease, defined as disease between birth and 6 days of life, or late onset invasive disease, defined as disease occurring between 7 and 89 days. In some instances, early onset disease i ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation

    SBC: IMMUNOPHOTONICS INC            Topic: 102

    Abstract: Immunophotonics is a biotech company developing a synthetic biopolymer, IP-001, to potentiate a systemic immunotherapy via microwave (MWA) thermal tumor ablation for treatment of Hepatocellular carcinoma (HCC). The goal of this SBIR Fast Track is to complete preclinical safety and efficacy testing to support an investigational new drug (IND) application based on the feedback from a meeti ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. SBIR Phase II:Aqueous Lithium and Zinc Ion Batteries for Stationary Energy Storage Applications

    SBC: AESIR TECHNOLOGIES INC            Topic: EW

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is the commercialization of an aqueous lithium and zinc ion battery that is a replacement for lead-acid and lithium-ion batteries in stationary energy storage applications.This battery has a nonflammable, environmentally-friendly, water-based electrolyte and does not utilize cobalt or nickel, reducing ...

    SBIR Phase II 2022 National Science Foundation
  10. STTR Phase II: Development of Safety Accessory for Improving Performance and Minimizing Complications of Manual Ventilation

    SBC: SAFEBVM CORP.            Topic: BM

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project will be to reduce the risk of complications and associated costs caused by standard bag valve mask (BVM) resuscitators, which are widely used in emergency resuscitation and airway management. In the United States, about 13.1 million BVMs are used annually. Medical providers frequently deliver ...

    STTR Phase II 2022 National Science Foundation
US Flag An Official Website of the United States Government